OptimizeRx Q2 GAAP net loss narrows to $0.7 million; revenue drops 30% to $20.5 million year over year
Reuters2026/08/12 20:03- OptimizeRx Q2 2026 revenue fell 30% to USD 20.5 million year over year.
- GAAP results swung to a net loss of USD 0.7 million, while adjusted EBITDA slipped to USD 4.9 million.
- Cash totaled USD 24.1 million at June 30, 2026; completed debt refinancing with a USD 35 million facility, including a USD 25 million term loan.
- CEO Stephen L. Silvestro said revenue pressure was concentrated among a small number of customers, with increased investment elsewhere in the base.
- Reaffirmed fiscal 2026 guidance for revenue of USD 95 million to USD 100 million; adjusted EBITDA seen at USD 21 million to USD 25 million.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
EUR/USD Price Forecast: Holds key 100-day SMA at start of the US CPI week
Paying the price for supporting the yen? Japan's foreign reserves fell by $87.8 billions in August, possibly due to selling US Treasuries for funding.
Japanese authorities may have used part of their foreign exchange reserves, including foreign securities such as U.S. Treasury bonds, over the past month to fund record-sized foreign exchange intervention operations.
10-Yr Benchmark Govt Yields - Germany vs Other Nations
10-Yr Benchmark Govt Yields - U.S. vs Other Nations
Crypto prices
More
